Omeros Corporation (OMER)

Biopharmaceutical company developing treatments for inflammation, central nervous system disorders, and other diseases.

OMER Stock Quote

Company Report

Omeros Corporation operates as a biopharmaceutical company at the forefront of discovering, developing, and commercializing small-molecule and protein-based therapeutics. Specializing in orphan indications and diseases linked to inflammation, complement-mediated disorders, dysfunctional immune systems in cancers, and addictive and compulsive disorders, Omeros focuses on addressing significant unmet medical needs.

Key clinical programs at Omeros include Narsoplimab (OMS721/MASP-2), which has completed pivotal studies for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (HSCT-TMA) and is currently in Phase III trials for immunoglobulin A nephropathy (IgAN) and atypical hemolytic uremic syndrome (aHUS). Additionally, Narsoplimab is undergoing Phase II trials for the treatment of COVID-19, showcasing its versatility in combating various conditions.

The company's diverse pipeline includes PPAR? (OMS405) in Phase II for opioid and nicotine addiction, and PDE7 (OMS527) in Phase I for addiction, compulsive disorders, and movement disorders. Omeros also advances MASP-3 (OMS906) in Phase I trials for paroxysmal nocturnal hemoglobinuria (PNH) and other disorders related to the alternative pathway.

In preclinical stages, Omeros is developing MASP-2 small-molecule inhibitors for aHUS, IgAN, HSCT-TMA, and age-related macular degeneration. The company is also exploring longer-acting second-generation antibodies targeting MASP-2 and MASP-3 small-molecule inhibitors for PNH and alternative pathway disorders. Moreover, Omeros is engaged in developing GPR174 Inhibitors, Chimeric Antigen Receptor (CAR) T-Cell, and Adoptive T-Cell Therapies for various cancers, alongside G protein-coupled receptor targets for a broad spectrum of disorders.

Founded in 1994 and headquartered in Seattle, Washington, Omeros Corporation continues to expand its innovative research and development efforts, positioning itself as a leader in advancing therapies for complex and underserved medical conditions worldwide.

OMER EPS Chart

OMER Revenue Chart

Stock Research

MGEE PANA TSE CLOE BVN AMPG STCN

OMER Chart

View interactive chart for OMER

OMER Profile

OMER News

Analyst Ratings